SK Chemicals applies for sales approval of dementia treatment from US FDA
A SK Chemicals’ patch-type dementia treatment will knock on the door of the U.S. market.
SK Chemicals(CEO Man-hoon Park) announced it completed application of the sales approval of ‘SID710,’ a patch-type dementia treatment, from the U.S. Food and Drug Administration on April 1(March 31 U.S. time...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
